Veracyte Inc
(FRA:12V)
€
39.4
0.8 (2.07%)
Market Cap: 3.16 Bil
Enterprise Value: 2.92 Bil
PE Ratio: 0
PB Ratio: 2.76
GF Score: 81/100 Veracyte Inc at Morgan Stanley Global Healthcare Conference (Virtual) Transcript
Sep 14, 2021 / 07:30PM GMT
Release Date Price:
€40.8
(-0.97%)
Tejas Rajeev Savant
Morgan Stanley, Research Division - Equity Analyst
Hey, everyone. Good afternoon. Thanks for joining us at our Healthcare Conference. I'm Tejas Savant, and I cover the Life Science Tools and Diagnostics sector here at Morgan Stanley. Delighted to have Veracyte join us today. And representing the Company are Marc Stapley, CEO; and Rebecca Chambers, CFO. Welcome to you both guys.
Before we begin, just some important disclosures I need to read out. Please see the Morgan Stanley Research Disclosure website at morganstanley.com/researchdisclosures. And if you have any questions, do reach out to your sales rep.
Marc, I believe you want to go through the safe harbor as well.
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot